» Articles » PMID: 30899441

Discovery of Lipid Biomarkers Correlated with Disease Progression in Clear Cell Renal Cell Carcinoma Using Desorption Electrospray Ionization Imaging Mass Spectrometry

Overview
Journal Oncotarget
Specialty Oncology
Date 2019 Mar 23
PMID 30899441
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Clear cell renal cell carcinoma (ccRCC) often results in recurrence or metastasis, and there are only a few clinically effective biomarkers for early diagnosis and personalized therapy. Metabolic changes have been widely studied using mass spectrometry (MS) of tissue lysates to identify novel biomarkers. Our objective was to identify lipid biomarkers that can predict disease progression in ccRCC by a tissue-based approach. We retrospectively investigated lipid molecules in cancerous tissues and normal renal cortex tissues obtained from patients with ccRCC ( = 47) using desorption electrospray ionization imaging mass spectrometry (DESI-IMS). We selected eight candidate lipid biomarkers showing higher signal intensity in cancerous than in normal tissues, with a clear distinction of the tissue type based on the images. Of these candidates, low maximum intensity ratio (cancerous/normal) values of ions of oleic acid, 389.2, and 391.3 significantly correlated with shorter progression-free survival compared with high maximum intensity ratio values ( = 0.011, = 0.022, and < 0.001, respectively). This study identified novel lipid molecules contributing to the prediction of disease progression in ccRCC using DESI-IMS. Our findings on lipid storage may provide a new diagnostic or therapeutic strategy for targeting cancer cell metabolism.

Citing Articles

Spatial-Omics Methods and Applications.

Kulasinghe A, Berrell N, Donovan M, Nilges B Methods Mol Biol. 2025; 2880:101-146.

PMID: 39900756 DOI: 10.1007/978-1-0716-4276-4_5.


Prognostic potential of lipid profiling in cancer patients: a systematic review of mass spectrometry-based studies.

Takanashi Y, Kahyo T, Sekihara K, Kawase A, Setou M, Funai K Lipids Health Dis. 2024; 23(1):154.

PMID: 38796445 PMC: 11128116. DOI: 10.1186/s12944-024-02121-0.


Recent Advances and Applications of Ambient Mass Spectrometry Imaging in Cancer Research: An Overview.

Kumar B Mass Spectrom (Tokyo). 2023; 12(1):A0129.

PMID: 37789912 PMC: 10542858. DOI: 10.5702/massspectrometry.A0129.


Medium-chain and long-chain fatty acids are associated with diarrheal predominant irritable bowel syndrome revealed by DESI-MSI.

Zhang Y, Zhu H, Du S, Wang H, Li H, Wang M J Gastroenterol. 2023; 58(11):1124-1133.

PMID: 37578536 PMC: 10590296. DOI: 10.1007/s00535-023-02030-6.


Spatial distribution of the Shannon entropy for mass spectrometry imaging.

Xu L, Kikushima K, Sato S, Islam A, Sato T, Aramaki S PLoS One. 2023; 18(4):e0283966.

PMID: 37023018 PMC: 10079050. DOI: 10.1371/journal.pone.0283966.


References
1.
Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

2.
Hsieh J, Purdue M, Signoretti S, Swanton C, Albiges L, Schmidinger M . Renal cell carcinoma. Nat Rev Dis Primers. 2017; 3:17009. PMC: 5936048. DOI: 10.1038/nrdp.2017.9. View

3.
Janzen N, Kim H, Figlin R, Belldegrun A . Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am. 2003; 30(4):843-52. DOI: 10.1016/s0094-0143(03)00056-9. View

4.
He M, Guo S, Li Z . In situ characterizing membrane lipid phenotype of breast cancer cells using mass spectrometry profiling. Sci Rep. 2015; 5:11298. PMC: 4462148. DOI: 10.1038/srep11298. View

5.
Gilchrist K, Gray R, Fowble B, Tormey D, Taylor 4th S . Tumor necrosis is a prognostic predictor for early recurrence and death in lymph node-positive breast cancer: a 10-year follow-up study of 728 Eastern Cooperative Oncology Group patients. J Clin Oncol. 1993; 11(10):1929-35. DOI: 10.1200/JCO.1993.11.10.1929. View